Tevogen Bio (NASDAQ:TVGN) Posts Earnings Results, Beats Expectations By $1.01 EPS

Tevogen Bio (NASDAQ:TVGN) released its quarterly earnings data on Thursday. The company reported ($1.52) earnings per share for the quarter, beating the consensus estimate of ($2.53) by $1.01, FiscalAI reports.

Tevogen Bio Trading Up 4.6%

Shares of TVGN stock traded up $0.30 during trading hours on Friday, hitting $6.87. The company’s stock had a trading volume of 8,215 shares, compared to its average volume of 12,930. The stock has a market cap of $28.98 million, a price-to-earnings ratio of -1.49 and a beta of 0.18. The business has a fifty day moving average of $6.94 and a 200-day moving average of $8.33. Tevogen Bio has a twelve month low of $3.64 and a twelve month high of $49.50.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $100.00.

Institutional Trading of Tevogen Bio

A number of institutional investors and hedge funds have recently bought and sold shares of TVGN. Goldman Sachs Group Inc. boosted its holdings in Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after acquiring an additional 152,572 shares during the period. Deutsche Bank AG grew its holdings in shares of Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after acquiring an additional 130,738 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its holdings in shares of Tevogen Bio by 66.7% during the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock worth $65,000 after buying an additional 33,000 shares during the period.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.